A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...
Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen ...
New Rochelle, NY, June 19, 2014—Plasminogen activators are proteins involved in the breakdown of blood clots, and an elevated level of plasminogen activator inhibitor-1 (PAI-1) is associated with an ...
Preoperative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC). This is an ASCO Meeting Abstract from the 2020 ...
Cardiac rupture is a fatal complication of acute myocardial infarction lacking treatment. Here, acute myocardial infarction resulted in rupture in wild-type mice and in mice lacking tissue-type ...
A new research paper was published in Volume 17, Issue 9 of Aging-US on September 11, 2025, titled "Roles of plasminogen activator inhibitor-1 in aging-related muscle and bone loss in mice." In this ...
Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab No significant financial ...
The global impact of the COVID-19 pandemic on healthcare systems has been significant. The sudden surge in infected cases overwhelmed hospitals and disrupted routine healthcare services, thus further ...
Intravenous recombinant tissue plasminogen activator can be used for the treatment of acute ischemic stroke in the elderly (age ≥80 years) within the NINDS rtPA protocol The study was a prospective ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback